You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Inhibitors of Mycobacterial Protein Tyrosine Phosphatase B (mPTPB) for therapy of

    SBC: AARDEN PHARMACEUTICALS, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Inhibitors of Mycobacterial Protein Tyrosine Phosphatase B (mPTPB) for therapy of tuberculosis Aarden Pharmaceuticals Project Summary/Abstract The need exists for a new, breakthrough therapeutic for tuberculosis (TB). Current treatment regimens with toxic chemotherapeutic drugs are too long, causing poor compliance which results in reduced efficacy and the emer ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  2. Biomarker discovery for immunodiagnosis of invasive candidiasis

    SBC: DXDISCOVERY INC            Topic: NIAID

    DESCRIPTION (provided by applicant): Invasive candidiasis (IC) is one of the most serious threats to patients in a critical setting. With as many as 60,000 cases per year in the U.S., the total cost associated with IC in the U.S. may be as high as 2-4 billion/year. One of the most critical factors influencing patient outcome is early diagnosis. The goal of this project is a rapi and inexpensive i ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  3. Elucidation of Antisickling Molecules in a Botanical with Antisickling Activity

    SBC: INVENUX, LLC            Topic: NCCAM

    DESCRIPTION: New therapeutic agents are urgently needed for the treatment of sickle cell disease (SCD), the world's most common genetic disease. Our long-term goal is to develop a drug for use in children that prevents the inexorable progression of SCD. SCD affects approximately 100,000 people in the United States and millions worldwide. It kills more children in Africa than HIV, but while HI ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  4. The anti-tumorigenic and anti-metastatic potential of Eya phosphatase inhibitors

    SBC: SIXONE SOLUTIONS, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): Breast cancer is expected to cause 39,510 deaths of American women in 2012 and 450,000 deaths globally. Once breast cancer has spread, it is essentially incurable. A critical barrier to treating advanced breast cancer is the lack of cancer-specific drugs that are effective in a large percentage of cancer patients and have low toxicity. Sixone Solutions, LLC pro ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  5. Proteomic differentiation of leukemia cells based on multiplexed arrays and mass

    SBC: TYMORA ANALYTICAL OPERATIONS LLC            Topic: NIGMS

    DESCRIPTION (provided by applicant): Although some gene mutations can predict response to certain targeted therapies, single-gene testing has limits. Multiple important signaling pathways that may be the causes of human malignancy have continuously been discovered and dissected. Pathway and network diagnostic tests are challenging but are clearly on the way. Through this NIH STTR Phase I study, we ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  6. Remote focusing through spatial light modulation for multifocal multiphoton micro

    SBC: BOULDER NONLINEAR SYSTEMS, INC.            Topic: NIMH

    DESCRIPTION (provided by applicant): Nonlinear optical microscopy techniques (such as two-photon florescence) are being used to acquire volumetric (i.e. three dimensional) images that probe several hundred microns into scattering tissue. These techniques are being combined with fast acquisition schemes to allow imaging of live, moving specimens at high NA. This combination allows for high-resoluti ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  7. Development of the Novel Small molecule drug Posiphen to treat Traumatic Brain In

    SBC: DIAMIR, LLC            Topic: NIA

    DESCRIPTION (provided by applicant): Alzheimer's Disease (AD) is the most common neurodegenerative disease: 5.4 million people are currently living with AD in the US, and up to 80 million Americans (over 55 years old) are considered to constitute the riskgroup for AD. In 2011, the annual cost of healthcare services for AD patients in the US reached 183 billion. There are currently no disease ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  8. Administrative supplement to 5R44DA025375-03: Prescription drug abuse prevention

    SBC: WELLGEN, INC.            Topic: NCCAM

    DESCRIPTION (provided by applicant): Type 2 Diabetes (T2D) is an inflammatory disease affecting 26 million people in the US (11%) and is predicted to affect more than 30% of adults in the US by 2050. The economic cost of T2D is over 200 billion a year. People with T2D suffer from hyperglycemia due to low insulin production, poor transport of insulin, or cellular resistance to insulin which can l ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  9. Novel VLP Adjuvant based on the VesiVax system

    SBC: Euclid Diagnostics LLC            Topic: NCI

    DESCRIPTION (provided by applicant): Over one million prostate biopsies are performed in the US each year to diagnose approximately 200,000 cases of prostate cancer. The majority of these biopsies are performed needlessly. The overall objective of this project is to develop a secondary prostate cancer diagnostic test that can be performed on men with elevated PSA in order to identify patients in n ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  10. Novel Vitamin B6 based prodrugs of gemcitabine

    SBC: MBC Pharma, Inc.            Topic: NCI

    DESCRIPTION (provided by applicant): The long-term goal of this proposal is to develop more effective therapies for cancer, specifically pancreatic cancer. The specific focus of this proposal is to improve upon the anti-cancer activity of the drug gemcytabine. This will be accomplished by synthesizing novel conjugates of gemcytabine in a form that enables increased pathways for uptake into cancer ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government